Quantitative EEG Evidence of Cognitive Restoration in Alzheimer’s Disease Following Biophoton Generator Therapy

Authors

  • James Z Liu First Institute of All Medicines, 139 Pittsburg Road, Butler, PA 16001, USA Author
  • Mariola A Smotrys First Institute of All Medicines, 139 Pittsburg Road, Butler, PA 16001, USA Author
  • Seth D Robinson Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA Author
  • Hui X Yu Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA Author
  • Sherry X Liu Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA Author
  • Devin R Liu Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA Author
  • Helen Y Gu First Institute of All Medicines, 139 Pittsburg Road, Butler, PA 16001, USA Author

DOI:

https://doi.org/10.47363/JNRRR/2025(7)224

Keywords:

Alzheimer’s Disease, Biophoton Therapy, Quantitative EEG, Neural Coherence, P300, Neuroplasticity, Electrophysiology

Abstract

Background: Alzheimer’s disease (AD) is marked by progressive cognitive and electrophysiological decline. Existing treatments offer limited symptomatic relief without reversing underlying pathology. Recent advances in biophoton therapy offer a novel, non-invasive strategy targeting mitochondrial and neural function.

Objective: To evaluate the neurophysiological and cognitive effects of biophoton generator therapy in AD patients using quantitative EEG (qEEG) metrics.

Methods: A randomized, triple-blinded, placebo-controlled clinical trial was conducted in 24 AD patients but 4 with serial EEG recordings were analyzed and reported in this article. Participants received nightly exposure to four strong biophoton generators for 2 to 4 weeks. Key EEG biomarkers assessed included posterior peak alpha frequency, theta/beta ratio, frontal alpha asymmetry, and P300 event-related potentials.

Results: Placebo-phase data showed negligible EEG changes. In contrast, 2 to 4 weeks of active treatment led to increased alpha and beta power, reduced delta/theta activity, improved interhemispheric coherence, elevated EEG entropy, and enhanced P300 amplitude with shorter latency. Improvements were consistent across spectral, topographic, and ERP domains, suggesting cognitive restoration and neural plasticity.

Conclusion: Strong biophoton generator therapy significantly improved qEEG biomarkers in AD patients within a short treatment window. These findings support further investigation into biophoton therapy as a safe, scalable intervention for neurodegenerative disorders.

Author Biographies

  • James Z Liu, First Institute of All Medicines, 139 Pittsburg Road, Butler, PA 16001, USA

    First Institute of All Medicines, 139 Pittsburg Road, Butler, PA 16001, USA

  • Mariola A Smotrys, First Institute of All Medicines, 139 Pittsburg Road, Butler, PA 16001, USA

    First Institute of All Medicines, 139 Pittsburg Road, Butler, PA 16001, USA

  • Seth D Robinson, Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA

    Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA

  • Hui X Yu, Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA

    Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA

  • Sherry X Liu, Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA

    Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA

  • Devin R Liu, Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA

    Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA

  • Helen Y Gu, First Institute of All Medicines, 139 Pittsburg Road, Butler, PA 16001, USA

    First Institute of All Medicines, 139 Pittsburg Road, Butler, PA 16001, USA

Downloads

Published

2025-07-22

Issue

Vol. 7 No. 7 (2025): Volume 7 Issue 7

Section

Articles